Abstract
Editorial: Orphan GPCRs As Emerging Drug Targets.
Highlights
Specialty section: This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology
The pace of G protein coupled-receptors (GPCRs)-targeted new molecular entities (NMEs) approved by the US Food and Drug Administration (FDA) in the recent years still remains to a level near its historical average, with five in 2010, five in 2011, seven in 2012, six in 2013, and eight in 2014
Out of total 219 NMEs approved by the FDA from 2005 to 2014, 54 (25%) target GPCRs
Summary
Specialty section: This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology. Editorial: Orphan GPCRs As Emerging Drug Targets This is in part due to the involvement of GPCRs in regulating a wide range of human physiological and pathophysiological processes, and in part due to the fact that current GPCR drugs only target ∼80 known receptors, about 10% of all GPCRs encoded in the human genome.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
